A core group translating innovative technology
Cadre Bioscience aims to accelerate the development of
early-stage therapeutics for multiple technology assets
cadre noun | ka-drā
a group of trained individuals that have a unifying relationship and goal
At Cadre Bioscience, we are a core group of people, technologies, and resources focused on a portfolio of early-stage therapeutic assets with high commercial potential and funneling them through a rigorous de-risking and development process. Utilizing a centralized management team, facilities, and operations to serve multiple technology assets, Cadre’s structure creates greater efficiencies, decreased timelines, and increased assurance that the best assets are advanced through critical pathways.
The traditional route of pursuing a commercial path for a therapeutic asset via an early stage start-up comes with numerous challenges, notably the raising of capital and attracting management while initiating a development plan. In certain markets and geographic regions, these factors may be an even greater challenge. Furthermore, the practice of building a company around a single technology during the earliest stages of development is inherently inefficient. Cadre Bioscience provides an attractive means for innovators to launch their technology down a commercialization path for market access and patient benefit.
In the end, the objective at Cadre Bioscience is to rapidly advance the development of therapeutic assets and spin them out as standalone companies that are poised to attract venture capital funding, recruit an experienced leadership team, and define a clear clinical strategy.
Bob Karr, MD
Executive Chairman & CEO
Bob Karr is a physician and scientist with over 25 years of senior executive experience in pharma and biotech, including discovery research, IND-enabling studies, clinical development and fundraising. Following roles in large pharma at G.D. Searle, Warner-Lambert and Pfizer, he served as President of Idera Pharmaceuticals in Cambridge, MA from 2005-2007 and on the Idera Board of Directors 2005-2015. Since 2008, Bob has focused on early stage biotechnology companies in St. Louis, MO. He served as President and CEO of Vasculox (now Arch Oncology) 2010-2015 and Chief Scientific Officer 2015-2017 after the company attracted venture capital investors.
Michael A. Tones, PhD
Chief Scientific Officer
Dr Tones’ pharmaceutical and start-up medical device company experience comprises nearly 30 years of R&D project leadership from Discovery to Clinical Development stages. Having worked for Ciba Pharmaceuticals and Pfizer in the UK, Switzerland and the US, Dr Tones is a biochemist by training and a translational pharmacologist by vocation, contributing to the identification of novel compound classes and drug repositioning opportunities in cardiovascular, neurological, metabolic and rare disease areas. Dr Tones has been Pl on several small business grant projects and serves on the BioGenerator mock review panel for SBIR/STTR applications.
Who We’re Looking For
Cadre Bioscience seeks partnerships with scientific inventors who have a therapeutic asset suitable for commercial development. We are a plug-and-play model for early-stage therapeutic development, providing an accelerated process that is ready for immediate implementation. The team, facilities and resources are all in place. Cadre manages day-to-day operations, provides capital for accelerating development, and implements a sound commercialization plan.
By partnering with Cadre, inventors can avoid the challenges and logistics of forming a company, raising capital, and hiring a management and scientific team. Instead, inventors can continue to focus on their research pursuits, serve as a scientific advisor to Cadre, and provide the deep knowledge and scientific understanding required to develop future therapies.